Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | TOP2A | P11388 | 2/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatinine SCHEMBL2248139 | 0.90 | CRBN (0.56) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| Creatinine SCHEMBL28491793 | 0.90 | CRBN (0.56) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| Creatinine SCHEMBL16295 | 0.89 | — | — | |
| Creatinine SCHEMBL7203535 | 0.89 | — | — | |
| Creatinine SCHEMBL8809815 | 0.89 | CRBN (0.61) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| Creatinine SCHEMBL288087 | 0.89 | CRBN (0.61) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| Creatinine SCHEMBL8637084 | 0.87 | — | — | |
| Creatinine SCHEMBL3514057 | 0.87 | — | — | |
| Creatinine SCHEMBL21404081 | 0.87 | — | — | |
| Creatinine SCHEMBL6473476 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-03-02 | — | — | US | disclosed |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | THERMOLIFE INTERNATIONAL, LLC (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2021-08-19 | — | — | US | disclosed |
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2019191338-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | CRBN 225/4885TOP2A 1856/4885TOP2B 2182/4885 |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | MB, CKMT1A; CKMT1B, REN | CRBN 225/4885TOP2A 1856/4885TOP2B 2182/4885 |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | CRBN 591/4885TOP2A 2692/4885TOP2B 2677/4885 |
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | CRBN 842/4885TOP2A 2223/4885TOP2B 2553/4885 |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | CRBN 591/4885TOP2A 2692/4885TOP2B 2677/4885 |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | CRBN 225/4885TOP2A 1856/4885TOP2B 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.